https://www.selleckchem.com/products/gant61.html
In recent years increasing options for systemic HCC treatment have become available. The development of therapy-specific prognostic scores has been encouraged. Tailoring therapy to individual patients requires prognostic scores for treatment success in addition to the Barcelona-Clinic-Liver-Cancer (BCLC) classification. We have developed and validated a prognostic score for patients treated with sorafenib. Prognostic factors identified in a multivariate analysis of 108 sorafenib patients were used to construct the Munich-Sorafenib-Evalua
Like
Comment
Share
